Publication
Abstract
A Phase III, Randomized, Double-Blind, Placebo controlled, Multicentre Study to evaluate the efficacy and safety of Etrolizumab as an Induction and Maintence Treatment for Patients with Moderately to Severely Active Crohnś Disease